Pfizer’s reset year starts with a little profit

Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.

Hello, everyone. Damian here with the final act in a pharmaceutical saga, the debate of Vertex Pharmaceuticals’ success, and news on 23andMe’s ongoing transformation.

The need-to-know this morning

• Novo Nordisk said it is increasing the availability of its blockbuster obesity drug Wegovy for new U.S. patients. The Danish drugmaker reported a 31% increase in sales for 2023 and issued better-than-expected guidance for 2024.
• GSK reported fourth quarter and 2023 earnings, and so did Novartis.

Adieu to Aduhelm

Years after a polarizing FDA decision and an ensuing commercial disaster, Biogen is finally parting ways with Aduhelm, its first approved medicine for Alzheimer’s disease.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus in-depth analysis, newsletters, premium events, and networking platform access.

Already have an account? Log in

Already have an account? Log in

Individual plans

Group plans

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe

Log In